| --- | --- | --- | --- | --- | --- | |---------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Delivering on the Promise | | | | | | | of Targeted Protein | | | | | | | Degradation | | | | | | | 40 th Annual J.P. Morgan Healthcare Conference | | | | | | | January 10, 2022 | | | | | | Forward-looking Statements and Intellectual Property Forward-looking Statements The following presentation contains forward-looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39567 C4 Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39567 C4 Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Company Overview - C4 Therapeutics is developing targeted protein degradation medicines to transform patient care[7] - The company has a strong balance sheet with $346 million in cash as of March 31, 2021[7] - The TORPEDO platform has the potential to efficiently design highly potent degrader medicines[7] - C4 Therapeutics has three partnerships that expand platform potential, with up to $2 billion in potential milestones[7] Pipeline and Programs - The company expects 4 programs to be in the clinic by the end of 2022[7] - There are 14 additional programs in earlier pre-clinical development[7] - IKZF1/3 degrader CFT7455 is in Phase 1/2 trial, with first clinical data expected in 2022[39, 71] - BRD9 degrader CFT8634 IND submission is expected in the second half of 2021[48] - EGFR degrader CFT8919 IND submission is expected mid-2022, with potential Phase 1/2 trial initiation by the end of 2022[55] Targeted Protein Degradation - Targeted protein degradation has the potential to drug the remaining ~85% of the human proteome and overcome resistance to existing inhibitor medicines[5] - Oncology small molecule therapies generated $63 billion in global revenue in 2018 despite known limitations[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39567 C4 Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39567 C4 Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-5617627 (State or other jurisdiction o ...

Corporate Presentation January 2021 Forward-looking Statements and Intellectual Property Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39567 C4 Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) De ...